Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5413587 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1LMNAGAAHTT | |
| SCHEMBL5344420 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1LMNAGAAHTT | |
| SCHEMBL6425835 | 0.83 | KDM4E (0.39) | KDM4EALDH1A1LMNAGAAHTT | |
| SCHEMBL22534064 | 0.83 | KDM4E (0.39) | KDM4EALDH1A1LMNAGAAHTT | |
| SCHEMBL9302479 | 0.82 | CCR2 (0.31) | — | |
| SCHEMBL8634789 | 0.77 | CTRB1 (0.35) | — | |
| SCHEMBL553861 | 0.77 | CTRB1 (0.35) | — | |
| SCHEMBL3596240 | 0.77 | CTRB1 (0.35) | — | |
| SCHEMBL10487291 | 0.77 | KDM4E (0.35) | KDM4EALDH1A1LMNAGAAHTT | |
| SCHEMBL10873133 | 0.76 | KDM4E (0.36) | KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145130-B2 | Multimodal adsorption medium with multimodal ligands, method for the preparation and use thereof | SARTORIUS STEDIM BIOTECH GMBH (DE) | 2024-11-19 | — | — | US | disclosed |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11285147-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220055015-A1 | MULTIMODAL ADSORPTION MEDIUM WITH MULTIMODAL LIGANDS, METHOD FOR THE PREPARATION AND USE THEREOF | SARTORIUS STEDIM BIOTECH GMBH (DE) | 2022-02-24 | — | — | US | disclosed |
| US-20210046428-A1 | FUNCTIONALISED MIXED MATRIX MEMBRANES AND METHOD OF PRODUCTION | HURRAH SARL (LU) | 2021-02-18 | — | — | US | disclosed |
| EP-3765176-A1 | FUNCTIONALISED MIXED MATRIX MEMBRANES AND METHOD OF PRODUCTION | HurraH S.à r.l. (LU) | 2021-01-20 | — | — | EP | disclosed |
| EP-3752145-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | Cytosite Biopharma Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2020-11-26 | — | — | US | disclosed |
| EP-3442700-B1 | MULTIMODAL ADSORPTION MEDIUM WITH MULTIMODAL LIGANDS, METHOD FOR THE PREPARATION AND USE THEREOF | SARTORIUS STEDIM BIOTECH GMBH (DE) | 2020-05-20 | — | — | EP | disclosed |
| US-20010016731-A1 | Methods and apparatus for accelerated orthokeratology | DEVORE DALE (US) | 2001-08-23 | — | — | US | disclosed |
| CN-1295677-A | Method and apparatus for accelerated orthokeratology | EASTA PHARMACEUTICALS INC (US) | 2001-05-16 | — | — | CN | disclosed |
| US-6161544-A | Methods for accelerated orthokeratology | KERATOFORM, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1051655-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | Ista Pharmaceuticals, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999039238-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | KERATOFORM, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| EP-0517788-B1 | 19 F LABELLED COMPOUNDS AS NMR IMAGING AND SPECTROSCOPY AGENTS | UNIV TEXAS (US) | 1995-08-02 | — | — | EP | disclosed |
| US-5422094-A | Administering to a human a fluorine-19 isotope containing compound, and monoclonal antibody which bound to above sensor reacts with tumor antigen and gives diagnostic signals | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-06-06 | — | — | US | disclosed |
| US-5236694-A | Free of background signals; having fluorinated alkyls, acetates, aniline and phosphonate moieties; | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0517788-A1 | 19 F LABELLED COMPOUNDS AS NMR IMAGING AND SPECTROSCOPY AGENTS. | UNIV TEXAS (US) | 1992-12-16 | — | — | EP | disclosed |
| WO-1991012824-A2 | 19F LABELLED COMPOUNDS AS NMR IMAGING AND SPECTROSCOPY AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145130-B2 | Multimodal adsorption medium with multimodal ligands, method for the preparation and use thereof | NEFM, ADM2, IGFBP4 | KDM4E 4584/4885ALDH1A1 3144/4885LMNA 2808/4885 |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | KDM4E 4784/4885ALDH1A1 4592/4885LMNA 783/4885 |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | KDM4E 4784/4885ALDH1A1 4592/4885LMNA 783/4885 |
| US-11285147-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | PARK7, SMN1; SMN2, CLN6 | KDM4E 2668/4885ALDH1A1 523/4885LMNA 1185/4885 |
| US-20220055015-A1 | MULTIMODAL ADSORPTION MEDIUM WITH MULTIMODAL LIGANDS, METHOD FOR THE PREPARATION AND USE THEREOF | NEFM, ADM2, IGFBP4 | KDM4E 4584/4885ALDH1A1 3144/4885LMNA 2808/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | KDM4E 4784/4885ALDH1A1 4592/4885LMNA 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.